Wolverine Trading
LFCR icon

Wolverine Trading’s Lifecore Biomedical LFCR Stock Holding History

Wolverine Trading’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,239
Closed -$77.3K – 4885
2023
Q3 		$77.3K Buy
+10,239
New +$93.6K ﹤0.01% 4071

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VWA
Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return

Wolverine Trading's LFCR Position: Q4 2023 in Review

Wolverine Trading sold out of Lifecore Biomedical (LFCR) in Q4 2023, closing a stake of 10,239 shares — an estimated $77.3K sold.

Wolverine Trading first reported a position in LFCR in Q3 2023 and held it in 1 quarter. The position peaked at $77.3K in Q3 2023. 78 funds tracked by Wall St. Rank hold LFCR as of Q4 2023.

  • Wolverine Trading reported no remaining Lifecore Biomedical position as of Q4 2023 after selling out during the quarter.
  • Wolverine Trading sold 10,239 Lifecore Biomedical shares in Q4 2023, an estimated $77.3K.
  • Wolverine Trading first reported a position in Lifecore Biomedical in Q3 2023 and held it in 1 quarter.
  • Wolverine Trading's Lifecore Biomedical position peaked at $77.3K in Q3 2023.
  • 78 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2023.

Based on Wolverine Trading's 13F filing for Q4 2023, filed 14 Feb 2024.